New cancer immunotherapy drugs rapidly reach patients after approval

(Yale University) The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study. The finding suggests that cancer immunotherapies are adopted at a much quicker pace than is typical for newly approved medical treatments, the researchers said.

Comments
%d bloggers like this: